Alethia Biotherapeutics

Alethia Biotherapeutics is a clinical-stage biotechnology company developing antibody therapies that make tumors responsive to cancer treatment by inhibiting the epithelial-mesenchymal transition and remodeling the immunosuppressive tumor microenvironment rather than activating the immune system directly. The company discovers and develops therapeutic monoclonal antibodies against tissue-specific novel targets. Its lead asset, sotevtamab (AB-16B5), is a monoclonal antibody designed to block sCLU-driven EMT.

Sotevtamab is designed to complement rather than replace existing therapies. The company's approach aims to increase the effectiveness of standard chemotherapies by targeting mechanisms of chemoresistance and reestablishing antigen presentation.